ASCO 2019 – Kantar reviews results from phase 3 POLO trial

Lynparza is paving new ground in pancreatic cancer, aiming to establish a maintenance setting and patient segmentation based on a biomarker (gBRCA mt) in first-line metastatic disease.

Anna Boudoures from Kantar reviews the “practice-changing” results of the phase 3 POLO trial of AstraZeneca and Merck & Co’s drug, as presented at ASCO 2019 in Chicago.


Click here to view exclusive live coverage from ASCO 2019.